查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2021653

即時診斷設備市場預測至2034年－按產品類型、檢體類型、技術、應用、最終用戶和地區分類的全球分析

Point-of-Care Diagnostic Devices Market Forecasts to 2034 - Global Analysis By Product Type, Sample Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球即時診斷設備市場規模將達到 480 億美元，並在預測期內以 7.5% 的複合年成長率成長，到 2034 年將達到 850 億美元。

即時診斷設備是攜帶式醫療設備，用於在患者就診地點或附近進行診斷測試。這些設備能夠快速檢測感染疾病、血糖值和心臟標記等疾病，從而支持即時的臨床決策。它們還能減少對中心檢查室檢測的需求，並提高醫療服務的效率。即時診斷設備廣泛應用於醫院、診所和家庭環境中，支援早期診斷、及時治療和改善患者預後，尤其是在急診和遠端醫療環境中。

慢性病增多

隨著糖尿病、心血管疾病和感染疾病的日益流行，對快速、準確且便捷的診斷解決方案的需求激增。即時檢測設備能夠實現即時檢測和結果回饋，從而支持及時的臨床決策並減少患者就診次數。其便攜性和易用性使其不僅適用於臨床環境，也適用於家庭環境。醫療專業人員正擴大採用這些設備來改善患者預後並減輕中心檢查室的負擔。鑑於慢性病在全球範圍內日益加重，對即時診斷的需求預計將持續強勁。

監理核准的挑戰

對臨床檢驗、安全性和準確性的嚴格要求常常導致產品上市延遲。製造商面臨著複雜且因地區而異的核准流程，這增加了成本並減緩了全球推廣。中小企業尤其難以克服這些監管障礙，限制了創新。醫療機構在獲得全面監管批准之前可能猶豫是否要引入新設備，這進一步延緩了產品的普及。儘管監管機構旨在確保病患安全，但漫長的核准週期卻阻礙了產品的快速商業化。

與數位健康平台整合

將醫療設備與行動應用、電子健康記錄和遠端醫療平台整合，可改善數據存取和病患監測。醫生可以遠端追蹤患者的檢測結果，從而實現預防性介入和個人化治療方案。檢測結果可以即時共用給醫療服務提供者，使患者受益，並提高就醫便利性和參與度。這種整合還支援大規模社區健康管理和慢性病監測。為了順應數位化醫療的發展趨勢，各公司正在增加對互聯診斷技術的投資。隨著醫療系統採用數位化優先模式，這些整合機會有望推動顯著成長。

低成本設備帶來的價格壓力

新興經濟體的許多本土製造商正在提供價格親民的即時檢測（PoC）解決方案，這對老牌大型企業構成了挑戰。在價格敏感的市場中，成本往往優先於先進功能，從而限制了高級產品的利潤空間。這種競爭環境迫使企業在創新與價格可負擔之間尋求平衡。醫療服務提供者可能會選擇更便宜的替代方案，即使這些方案缺乏先進的連接性或分析能力。商品化的威脅在血糖值監測和快速感染疾病檢測等領域尤為突出。

新冠疫情的影響：

新冠疫情顯著加速了即時診斷設備的應用。快速檢測對於控制疫情傳播至關重要，由此產生了對攜帶式診斷解決方案前所未有的需求。疫情期間，各國政府和醫療系統對即時檢測基礎設施進行了大量投資。疫情也凸顯了分散式診斷的重要性，有助於減少對集中式檢查室的依賴。疫情過後，隨著醫療服務提供者認知到快速診斷在慢性病管理和急診醫學的價值，這一趨勢仍在持續。製造商正利用從新冠疫情中汲取的經驗教訓，拓展產品系列併加強供應鏈。

在預測期內，免疫檢測領域預計將佔據最大的市場佔有率。

隨著慢性病盛行率的不斷上升，對快速、準確的生物標記檢測的需求日益成長，預計在預測期內，免疫檢測領域將佔據最大的市場佔有率。免疫檢測廣泛應用於感染疾病診斷、慢性病監測和癌症標記檢測。由於其多功能性和可靠性，免疫檢測是即時診斷的基礎。微流體技術和攜帶式平台的進步正在提高免疫檢測的效率。醫院、診所和居家醫療機構越來越依賴這些檢測來進行快速決策。已開發市場和新興市場對該領域的強勁需求都支撐著這一細分市場的發展。

在預測期內，居家照護環境細分市場預計將呈現最高的複合年成長率。

在預測期內，受慢性病患病率上升以及由此產生的對便捷家庭診斷解決方案的需求推動，居家照護環境領域預計將呈現最高的成長率。糖尿病、心血管疾病和呼吸系統疾病患者越來越依賴即時檢測設備進行自我管理。家庭診斷可以減少就醫次數，提高治療順從性，並幫助患者更好地掌控自身健康。這一領域受益於可與行動應用程式和遠端醫療平台整合的連網型設備的日益普及。不斷上漲的醫療保健成本和人口老化進一步推動了居家照護的轉型。製造商正致力於開發方便用戶使用、便於攜帶且針對家庭使用進行最佳化的設備。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的醫療保健基礎設施以及慢性病在總人口中日益普遍的患病率。美國在即時診斷技術的核准方面處於主導地位，這得益於其健全的報銷體系和法規核准。市場主要企業總部均設在該地區，推動創新和商業化進程。糖尿病、心血管疾病和癌症的高發生率推動了對快速診斷的需求。該地區還受益於數位健康平台和即時診斷設備的深度整合。對研發和臨床試驗的持續投入進一步鞏固了其市場領導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健的快速數位化以及新興經濟體慢性病盛行率的上升。中國、印度和東南亞等國家對價格合理且易於取得的診斷服務的需求日益成長。各國政府正在加大對醫療基礎設施的投資，並推廣分散式檢查以增強醫療公平性。本土製造商提供具成本效益的解決方案，促進了價格敏感型市場的普及。智慧型手機普及率的提高和遠端醫療措施正在推動即時檢測設備與數位平台的整合。預防醫學意識的增強也進一步推動了市場擴張。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球即時診斷設備市場：依產品類型分類

  • 血糖監測設備
  • 傳染病檢查設備
  • 心臟標記檢測裝置
  • 血液氣體和電解質分析儀
  • 其他產品類型

第6章 全球即時診斷設備市場：依樣本類型分類

  • 血
  • 尿
  • 唾液
  • 鼻咽拭子
  • 其他檢體類型

第7章 全球即時診斷設備市場：依技術分類

  • 橫向流動化驗
  • 免疫檢測
  • 分子診斷
  • 微流體技術
  • 生物感測器
  • 其他技術

第8章 全球即時診斷設備市場：按應用分類

  • 糖尿病檢測
  • 心血管疾病
  • 腫瘤檢查
  • 妊娠和不孕症檢查
  • 其他用途

第9章 全球即時診斷設備市場：依最終用戶分類

  • 醫院
  • 診所
  • 診斷中心
  • 居家醫療環境
  • 其他最終用戶

第10章 全球即時診斷設備市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Abbott Laboratories
  • Roche Diagnostics
  • Siemens Healthineers
  • Danaher Corporation
  • Becton Dickinson and Company
  • Bio-Rad Laboratories
  • QuidelOrtho Corporation
  • PerkinElmer Inc.
  • Sekisui Diagnostics
  • Trinity Biotech
  • Arkray Inc.
  • SD Biosensor Inc.
  • Werfen
  • Hologic Inc.
  • Fujifilm Holdings Corporation
Product Code: SMRC35102

According to Stratistics MRC, the Global Point-of-Care Diagnostic Devices Market is accounted for $48 billion in 2026 and is expected to reach $85 billion by 2034 growing at a CAGR of 7.5% during the forecast period. Point-of-Care Diagnostic Devices are portable medical tools used to perform diagnostic tests at or near the site of patient care. These devices provide rapid results for conditions such as infections, blood glucose levels, cardiac markers, and more, enabling immediate clinical decisions. They reduce the need for centralized laboratory testing and improve efficiency in healthcare delivery. Widely used in hospitals, clinics, and home settings, point-of-care devices support early diagnosis, timely treatment, and improved patient outcomes, particularly in emergency and remote care environments.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

Rising cases of diabetes, cardiovascular disorders, and infectious diseases have created urgent demand for rapid, accurate, and accessible diagnostic solutions. Point-of-care devices enable immediate testing and results, supporting timely clinical decisions and reducing hospital visits. Their portability and ease of use make them suitable for both clinical and home settings. Healthcare providers are increasingly adopting these devices to improve patient outcomes and reduce the burden on centralized laboratories. The growing global burden of chronic illnesses is expected to sustain strong demand for point-of-care diagnostics.

Restraint:

Regulatory approval challenges

Stringent requirements for clinical validation, safety, and accuracy often delay product launches. Manufacturers face complex approval processes across different regions, which increases costs and slow global expansion. Smaller companies, in particular, struggle to navigate these regulatory hurdles, limiting innovation. Healthcare providers may hesitate to adopt new devices until they receive full regulatory clearance, further slowing uptake. While regulatory bodies aim to ensure patient safety, the lengthy approval timelines remain a barrier to rapid commercialization.

Opportunity:

Integration with digital health platforms

Linking devices with mobile apps, electronic health records, and telehealth platforms enhances data accessibility and patient monitoring. Physicians can remotely track patient results, enabling proactive interventions and personalized treatment plans. Patients benefit from improved convenience and engagement, as results can be shared instantly with healthcare providers. This integration also supports population health management and chronic disease monitoring at scale. Companies are increasingly investing in connected diagnostics to align with digital health trends. As healthcare systems embrace digital-first models, integration opportunities are expected to drive significant growth.

Threat:

Pricing pressure from low-cost devices

Many local manufacturers in emerging economies offer affordable point-of-care solutions, challenging established players. Price-sensitive markets often prioritize cost over advanced features, limiting margins for premium products. This competitive environment forces companies to balance innovation with affordability. Healthcare providers may opt for cheaper alternatives, even if they lack advanced connectivity or analytics. The threat of commoditization is particularly strong in segments such as glucose monitoring and rapid infectious disease tests.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated the adoption of point-of-care diagnostic devices. Rapid testing became essential for managing infection spread, driving unprecedented demand for portable diagnostic solutions. Governments and healthcare systems invested heavily in point-of-care testing infrastructure during the crisis. The pandemic also highlighted the importance of decentralized diagnostics, reducing reliance on centralized laboratories. Post-pandemic, the momentum continues as healthcare providers recognize the value of rapid diagnostics for chronic disease management and emergency care. Manufacturers are leveraging lessons from COVID-19 to expand product portfolios and strengthen supply chains.

The immunoassays segment is expected to be the largest during the forecast period

The immunoassays segment is expected to account for the largest market share during the forecast period as the increasing prevalence of chronic diseases has heightened demand for rapid and accurate biomarker detection. Immunoassays are widely used for diagnosing infectious diseases, monitoring chronic conditions, and detecting cancer markers. Their versatility and reliability make them a cornerstone of point-of-care diagnostics. Advances in microfluidics and portable platforms are enhancing the efficiency of immunoassays. Hospitals, clinics, and home care settings increasingly rely on these tests for immediate decision-making. The segment benefits from strong demand across both developed and emerging markets.

The home care settings segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the home care settings segment is predicted to witness the highest growth rate due to the increasing prevalence of chronic diseases, which has driven demand for convenient, at-home diagnostic solutions. Patients with diabetes, cardiovascular disorders, and respiratory conditions increasingly rely on point-of-care devices for self-monitoring. Home-based diagnostics reduce hospital visits, improve adherence, and empower patients to manage their health. The segment benefits from growing adoption of connected devices that integrate with mobile apps and telehealth platforms. Rising healthcare costs and aging populations further support the shift toward home care. Manufacturers are focusing on user-friendly, portable devices tailored for home use.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to advanced healthcare infrastructure and the increasing prevalence of chronic diseases across the population. The U.S. leads in adoption of point-of-care diagnostics, supported by strong reimbursement frameworks and regulatory approvals. Major players in the market are headquartered in the region, driving innovation and commercialization. High incidence of diabetes, cardiovascular disorders, and cancer fuels demand for rapid diagnostics. The region also benefits from strong integration of digital health platforms with point-of-care devices. Ongoing investments in R&D and clinical trials further strengthen market leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid healthcare digitization and the increasing prevalence of chronic diseases in emerging economies. Countries such as China, India, and Southeast Asia are witnessing rising demand for affordable and accessible diagnostics. Governments are investing in healthcare infrastructure and promoting decentralized testing to improve equity. Local manufacturers are offering cost-effective solutions, boosting adoption in price-sensitive markets. Growing smartphone penetration and telehealth initiatives enhance integration of point-of-care devices with digital platforms. Rising awareness of preventive healthcare further supports market expansion.

Key players in the market

Some of the key players in Point-of-Care Diagnostic Devices Market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, QuidelOrtho Corporation, PerkinElmer Inc., Sekisui Diagnostics, Trinity Biotech, Arkray Inc., SD Biosensor Inc., Werfen, Hologic Inc. and Fujifilm Holdings Corporation.

Key Developments:

In March 2026, Arkray launched a portable HbA1c analyzer for diabetes management in outpatient clinics. The device provides immediate results, enabling clinicians to adjust treatment plans during patient visits. Arkray's innovation reinforces its focus on chronic disease management through point-of-care solutions.

In September 2025, Bio-Rad introduced a compact immunoassay analyzer for decentralized oncology testing. The system supports biomarker-guided therapy decisions, offering clinicians rapid results outside central labs. Bio-Rad's innovation reflects its focus on precision diagnostics and expanding access to personalized medicine tools.

In June 2025, Sekisui Diagnostics launched a rapid point-of-care test for C-reactive protein (CRP), supporting infection and inflammation management. The device offers results in under five minutes, aiding primary care decision-making. Sekisui's expansion into portable immunoassays strengthens its role in frontline diagnostics.

Product Types Covered:

  • Glucose Monitoring Devices
  • Infectious Disease Testing Devices
  • Cardiac Marker Testing Devices
  • Blood Gas & Electrolyte Analyzers
  • Other Product Types

Sample Types Covered:

  • Blood
  • Urine
  • Saliva
  • Nasal/Throat Swabs
  • Other Sample Types

Technologies Covered:

  • Lateral Flow Assays
  • Immunoassays
  • Molecular Diagnostics
  • Microfluidics
  • Biosensors
  • Other Technologies

Applications Covered:

  • Diabetes Testing
  • Cardiovascular Diseases
  • Oncology Testing
  • Pregnancy & Fertility Testing
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Point-of-Care Diagnostic Devices Market, By Product Type

  • 5.1 Glucose Monitoring Devices
  • 5.2 Infectious Disease Testing Devices
  • 5.3 Cardiac Marker Testing Devices
  • 5.4 Blood Gas & Electrolyte Analyzers
  • 5.5 Other Product Types

6 Global Point-of-Care Diagnostic Devices Market, By Sample Type

  • 6.1 Blood
  • 6.2 Urine
  • 6.3 Saliva
  • 6.4 Nasal/Throat Swabs
  • 6.5 Other Sample Types

7 Global Point-of-Care Diagnostic Devices Market, By Technology

  • 7.1 Lateral Flow Assays
  • 7.2 Immunoassays
  • 7.3 Molecular Diagnostics
  • 7.4 Microfluidics
  • 7.5 Biosensors
  • 7.6 Other Technologies

8 Global Point-of-Care Diagnostic Devices Market, By Application

  • 8.1 Diabetes Testing
  • 8.2 Cardiovascular Diseases
  • 8.3 Oncology Testing
  • 8.4 Pregnancy & Fertility Testing
  • 8.5 Other Applications

9 Global Point-of-Care Diagnostic Devices Market, By End User

  • 9.1 Hospitals
  • 9.2 Clinics
  • 9.3 Diagnostic Centers
  • 9.4 Home Care Settings
  • 9.5 Other End Users

10 Global Point-of-Care Diagnostic Devices Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Abbott Laboratories
  • 13.2 Roche Diagnostics
  • 13.3 Siemens Healthineers
  • 13.4 Danaher Corporation
  • 13.5 Becton Dickinson and Company
  • 13.6 Bio-Rad Laboratories
  • 13.7 QuidelOrtho Corporation
  • 13.8 PerkinElmer Inc.
  • 13.9 Sekisui Diagnostics
  • 13.10 Trinity Biotech
  • 13.11 Arkray Inc.
  • 13.12 SD Biosensor Inc.
  • 13.13 Werfen
  • 13.14 Hologic Inc.
  • 13.15 Fujifilm Holdings Corporation

List of Tables

  • Table 1 Global Point-of-Care Diagnostic Devices Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Point-of-Care Diagnostic Devices Market, By Product Type (2023-2034) ($MN)
  • Table 3 Global Point-of-Care Diagnostic Devices Market, By Glucose Monitoring Devices (2023-2034) ($MN)
  • Table 4 Global Point-of-Care Diagnostic Devices Market, By Infectious Disease Testing Devices (2023-2034) ($MN)
  • Table 5 Global Point-of-Care Diagnostic Devices Market, By Cardiac Marker Testing Devices (2023-2034) ($MN)
  • Table 6 Global Point-of-Care Diagnostic Devices Market, By Blood Gas & Electrolyte Analyzers (2023-2034) ($MN)
  • Table 7 Global Point-of-Care Diagnostic Devices Market, By Other Product Types (2023-2034) ($MN)
  • Table 8 Global Point-of-Care Diagnostic Devices Market, By Sample Type (2023-2034) ($MN)
  • Table 9 Global Point-of-Care Diagnostic Devices Market, By Blood (2023-2034) ($MN)
  • Table 10 Global Point-of-Care Diagnostic Devices Market, By Urine (2023-2034) ($MN)
  • Table 11 Global Point-of-Care Diagnostic Devices Market, By Saliva (2023-2034) ($MN)
  • Table 12 Global Point-of-Care Diagnostic Devices Market, By Nasal/Throat Swabs (2023-2034) ($MN)
  • Table 13 Global Point-of-Care Diagnostic Devices Market, By Other Sample Types (2023-2034) ($MN)
  • Table 14 Global Point-of-Care Diagnostic Devices Market, By Technology (2023-2034) ($MN)
  • Table 15 Global Point-of-Care Diagnostic Devices Market, By Lateral Flow Assays (2023-2034) ($MN)
  • Table 16 Global Point-of-Care Diagnostic Devices Market, By Immunoassays (2023-2034) ($MN)
  • Table 17 Global Point-of-Care Diagnostic Devices Market, By Molecular Diagnostics (2023-2034) ($MN)
  • Table 18 Global Point-of-Care Diagnostic Devices Market, By Microfluidics (2023-2034) ($MN)
  • Table 19 Global Point-of-Care Diagnostic Devices Market, By Biosensors (2023-2034) ($MN)
  • Table 20 Global Point-of-Care Diagnostic Devices Market, By Other Technologies (2023-2034) ($MN)
  • Table 21 Global Point-of-Care Diagnostic Devices Market, By Application (2023-2034) ($MN)
  • Table 22 Global Point-of-Care Diagnostic Devices Market, By Diabetes Testing (2023-2034) ($MN)
  • Table 23 Global Point-of-Care Diagnostic Devices Market, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 24 Global Point-of-Care Diagnostic Devices Market, By Oncology Testing (2023-2034) ($MN)
  • Table 25 Global Point-of-Care Diagnostic Devices Market, By Pregnancy & Fertility Testing (2023-2034) ($MN)
  • Table 26 Global Point-of-Care Diagnostic Devices Market, By Other Applications (2023-2034) ($MN)
  • Table 27 Global Point-of-Care Diagnostic Devices Market, By End User (2023-2034) ($MN)
  • Table 28 Global Point-of-Care Diagnostic Devices Market, By Hospitals (2023-2034) ($MN)
  • Table 29 Global Point-of-Care Diagnostic Devices Market, By Clinics (2023-2034) ($MN)
  • Table 30 Global Point-of-Care Diagnostic Devices Market, By Diagnostic Centers (2023-2034) ($MN)
  • Table 31 Global Point-of-Care Diagnostic Devices Market, By Home Care Settings (2023-2034) ($MN)
  • Table 32 Global Point-of-Care Diagnostic Devices Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.